P-PSMA-ALLO1
Metastatic Castration-Resistant Prostate Cancer
Phase 1Active (Transferred to Roche)
Key Facts
Indication
Metastatic Castration-Resistant Prostate Cancer
Phase
Phase 1
Status
Active (Transferred to Roche)
Company
About Poseida Therapeutics
Poseida Therapeutics was a San Diego-based biotech focused on developing next-generation cell and gene therapies with its non-viral engineering platforms. Its core strategy centered on overcoming the limitations of viral vectors to create CAR-T products with a high proportion of stem cell memory T cells for enhanced persistence and potency. The company advanced a pipeline of autologous and allogeneic CAR-T candidates targeting hematological malignancies and solid tumors. Its significant technological achievements culminated in its acquisition by Roche in 2024, validating its platform and providing a path for accelerated development.
View full company profileTherapeutic Areas
Other Metastatic Castration-Resistant Prostate Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| KEYTRUDA (pembrolizumab) | Merck | Phase 3 |
| MK-5684 | Merck | Phase 3 |
| TAK-280 | Thermo Fisher Scientific | Phase 2 |
| PNT2001 | Lantheus Holdings | Phase 3 |
| ARV-766 | Arvinas | Phase 2 |
| Bavdegalutamide (ARV-110) | Arvinas | Phase 2 |